254 related articles for article (PubMed ID: 12376975)
1. Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor.
Modak S; Gerald W; Cheung NK
Med Pediatr Oncol; 2002 Dec; 39(6):547-51. PubMed ID: 12376975
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors.
Modak S; Kramer K; Gultekin SH; Guo HF; Cheung NK
Cancer Res; 2001 May; 61(10):4048-54. PubMed ID: 11358824
[TBL] [Abstract][Full Text] [Related]
3. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis.
Cheresh DA; Rosenberg J; Mujoo K; Hirschowitz L; Reisfeld RA
Cancer Res; 1986 Oct; 46(10):5112-8. PubMed ID: 3019521
[TBL] [Abstract][Full Text] [Related]
4. Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Clin Cancer Res; 1998 Sep; 4(9):2135-9. PubMed ID: 9748131
[TBL] [Abstract][Full Text] [Related]
5. Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S; Cheung NK
Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
[TBL] [Abstract][Full Text] [Related]
6. Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2.
Occhino M; Raffaghello L; Burrone O; Gambini C; Pistoia V; Corrias MV; Bestagno M
Int J Mol Med; 2004 Sep; 14(3):383-8. PubMed ID: 15289889
[TBL] [Abstract][Full Text] [Related]
7. Induction of Ab3 and Ab3' antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma.
Cheung NK; Guo HF; Heller G; Cheung IY
Clin Cancer Res; 2000 Jul; 6(7):2653-60. PubMed ID: 10914706
[TBL] [Abstract][Full Text] [Related]
8. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
Mujoo K; Cheresh DA; Yang HM; Reisfeld RA
Cancer Res; 1987 Feb; 47(4):1098-104. PubMed ID: 3100030
[TBL] [Abstract][Full Text] [Related]
9. Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens.
Zhang S; Zhang HS; Cordon-Cardo C; Ragupathi G; Livingston PO
Clin Cancer Res; 1998 Nov; 4(11):2669-76. PubMed ID: 9829729
[TBL] [Abstract][Full Text] [Related]
10. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E
Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495
[TBL] [Abstract][Full Text] [Related]
11. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma.
Bolli M; Kocher T; Adamina M; Guller U; Dalquen P; Haas P; Mirlacher M; Gambazzi F; Harder F; Heberer M; Sauter G; Spagnoli GC
Ann Surg; 2002 Dec; 236(6):785-93; discussion 793. PubMed ID: 12454517
[TBL] [Abstract][Full Text] [Related]
12. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
[TBL] [Abstract][Full Text] [Related]
13. Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: novel targets for therapy.
Fine RL; Shah SS; Moulton TA; Yu IR; Fogelman DR; Richardson M; Burris HA; Samuels BL; Assanasen C; Gorroochurn P; Hibshoosh H; Orjuela M; Garvin J; Goldman FD; Dubovsky D; Walterhouse D; Halligan G
Cancer Chemother Pharmacol; 2007 Mar; 59(4):429-37. PubMed ID: 16896931
[TBL] [Abstract][Full Text] [Related]
14. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotype of desmoplastic small round cell tumors as detected in cases with EWS-WT1 gene fusion product.
Zhang PJ; Goldblum JR; Pawel BR; Fisher C; Pasha TL; Barr FG
Mod Pathol; 2003 Mar; 16(3):229-35. PubMed ID: 12640103
[TBL] [Abstract][Full Text] [Related]
16. Ganglioside antigens expressed by human cancer cells.
Ritter G; Livingston PO
Semin Cancer Biol; 1991 Dec; 2(6):401-9. PubMed ID: 1810468
[TBL] [Abstract][Full Text] [Related]
17. Tumor antigens in astrocytic gliomas.
Kurpad SN; Zhao XG; Wikstrand CJ; Batra SK; McLendon RE; Bigner DD
Glia; 1995 Nov; 15(3):244-56. PubMed ID: 8586461
[TBL] [Abstract][Full Text] [Related]
18. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients.
Schulz G; Cheresh DA; Varki NM; Yu A; Staffileno LK; Reisfeld RA
Cancer Res; 1984 Dec; 44(12 Pt 1):5914-20. PubMed ID: 6498849
[TBL] [Abstract][Full Text] [Related]
19. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy.
Kushner BH; Cheung IY; Kramer K; Modak S; Cheung NK
Pediatr Blood Cancer; 2007 Apr; 48(4):430-4. PubMed ID: 16421906
[TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]